经济观察报 见习记者 刘晓诺 自称"已陷入生死存亡的困境"的*ST苏吴（600200.SZ），把AestheFill"童颜针"代理权之争推进到了法律层面。 8月11日晚，*ST苏吴发布公告，其控股孙公司达透医疗器械（上海）有限公司（下称"达透公司"）已向深圳国际仲裁院申请仲裁，并已于8月7日 获受理立案。仲裁的另一方当事人，便是爱美客（300896.SZ）间接控股的韩国公司REGEN Biotech,Inc.（下称"REGEN"）。 达透公司的核心仲裁请求是，确认达透公司具有对AestheFill的独家代理权，且REGEN需要继续向达透公司供货。 达透公司进一步主张，若不能确认其具有AestheFill的独家代理权，将要求REGEN公司支付暂计16亿元的赔偿，且达透公司将保留调整前述索赔金 额的权利。 8月12日，爱美客相关负责人告诉经济观察报，爱美客对*ST苏吴方面提起仲裁并不意外，但目前还未正式收到仲裁机构的口头或书面通知。 爱美客相关负责人认为："既然已经诉诸法律，相信深圳国际仲裁院会根据仲裁规则，公平合理解决争议。走法律程序的目的还是为了解决争议， 不是为了发泄情绪。" 他认为，正在进行的法律程序不会 ...

Core Viewpoint - *ST Suwu is facing significant challenges, including potential delisting risks due to regulatory violations, loss of exclusive distribution rights for its key product AestheFill, and the freezing of its major shareholder's shares, leading to a precarious financial situation [2][8]. Group 1: Regulatory and Legal Issues - On July 13, *ST Suwu received a notice from the China Securities Regulatory Commission regarding administrative penalties for false reporting in its annual reports from 2020 to 2023, indicating a risk of forced delisting [2]. - The company’s major shareholder, Suzhou Wuzhong Investment Holding Co., has had 123 million shares frozen by the Suzhou Intermediate People's Court, raising concerns about the stability of the company's share structure [7][8]. Group 2: Loss of Distribution Rights - On July 18, *ST Suwu's subsidiary, Datou Medical, received a termination letter from Regen Biotech, ending its exclusive distribution agreement for AestheFill in mainland China [3][4]. - Regen Biotech, now controlled by domestic medical beauty giant Aimeike, cited violations of the distribution agreement by Datou Medical, claiming that the distribution rights had effectively been transferred to its parent company, Wuzhong Medical [4][5]. Group 3: Financial Impact - AestheFill is a critical product for *ST Suwu, contributing approximately 3.30 billion yuan in revenue for 2024, with AestheFill sales alone accounting for 3.26 billion yuan, representing 20.42% of total revenue [6]. - The company previously indicated that the profitability for 2024 would largely depend on the sales of AestheFill, which has been a significant driver of its financial performance [6]. Group 4: Market Reactions and Future Outlook - Following the series of negative events, *ST Suwu's stock has experienced a continuous decline, hitting a limit down for nine consecutive trading days, with a closing price of 1.54 yuan per share, nearly halving compared to the same period last year [2]. - The company has initiated a response plan to address the distribution rights dispute and is prepared to take legal action if necessary [4][6].